Core Viewpoint - A securities class action lawsuit has been filed against Neumora Therapeutics, Inc. in the Southern District of New York, concerning alleged misleading statements in the company's Offering Documents related to its initial public offering on September 15, 2023 [1]. Group 1: Allegations Against Neumora - The lawsuit claims that Neumora made materially false and/or misleading statements in its Offering Documents [2]. - It is alleged that Neumora amended the Phase Two Trial inclusion criteria to include patients with moderate to severe major depressive disorder (MDD) to justify its Phase Three Program [2]. - The complaint also states that the Phase Two Trials lacked adequate data regarding patient population size and gender ratio, which could affect the predictability of the KOASTAL-1 study results [2]. Group 2: Lead Plaintiff Process - Investors in Neumora have until April 7, 2025, to seek appointment as a lead plaintiff representative of the class [3]. - A lead plaintiff acts on behalf of all class members and typically has the largest financial interest in the case [3]. - The decision to serve as a lead plaintiff does not affect an investor's ability to share in any recovery from the lawsuit [3]. Group 3: Law Firm Information - Kessler Topaz Meltzer & Check, LLP is handling the class action and encourages affected investors to contact them for more information [4]. - The firm has a reputation for prosecuting class actions and has recovered billions for victims of corporate misconduct [4].

Core Viewpoint - A securities class action lawsuit has been filed against Neumora Therapeutics, Inc. for allegedly making materially false and misleading statements in its Offering Documents related to its initial public offering [1]. Group 1: Allegations Against Neumora - The lawsuit claims that Neumora amended its Phase Two Trial inclusion criteria to include patients with moderate to severe major depressive disorder (MDD) to justify its Phase Three Program [3]. - It is alleged that Neumora added a prespecified analysis to the Phase Two statistical analysis plan, focusing on patients suffering from moderate to severe MDD [3]. - The complaint states that the Phase Two Trials lacked adequate data regarding patient population size and gender ratio, which could affect the predictability of the KOASTAL-1 study results [3]. Group 2: Lead Plaintiff Process - Investors in Neumora have until April 7, 2025, to seek appointment as a lead plaintiff representative of the class through Kessler Topaz Meltzer & Check, LLP or other counsel [4]. - A lead plaintiff acts on behalf of all class members and is typically the investor or small group of investors with the largest financial interest [4]. - The decision to serve as a lead plaintiff does not affect an investor's ability to share in any recovery [4].

NEW YORK, April 4, 2025 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Neumora Therapeutics, Inc. (NASDAQ: NMRA) pursuant and/or traceable to the registration statement and related prospectus (collectively, the "Offering Documents") issued in connection with Neumora's September 2023 initial public offering (the "IPO"), of the important April 7, 2025 lead plaintiff deadline in the securities class action first filed by the firm.So what: If you purchas ...

Core Viewpoint - Neumora Therapeutics, Inc. is facing a federal securities class action lawsuit due to allegations of misleading statements and inadequate data regarding its clinical trials, leading to significant investor losses following the failure of its experimental depression treatment [4][5]. Group 1: Legal Actions and Investigations - Faruqi & Faruqi, LLP is investigating potential claims against Neumora and has set an April 7, 2025 deadline for investors to seek the role of lead plaintiff in the class action lawsuit [2]. - The lawsuit alleges that Neumora and its executives violated federal securities laws by making false statements and failing to disclose critical information about their clinical trials [4]. Group 2: Financial Impact - Following the announcement of the failure of its depression treatment in the Phase III Koastal-1 trial, Neumora's stock price dropped by 81%, closing at $1.97 per share on January 2, 2025 [5]. - Investors who suffered losses exceeding $50,000 due to the IPO and related documents are encouraged to contact the law firm for discussions on their legal rights [1]. Group 3: Clinical Trial Issues - The complaint highlights that Neumora had to amend the original Phase Two Trial inclusion criteria to include a patient population with moderate to severe Major Depressive Disorder (MDD) to demonstrate the efficacy of navacaprant [4]. - It is claimed that the Phase Two Trials lacked adequate data, particularly regarding patient population size and gender ratio, which undermined the predictive accuracy for the subsequent KOASTAL-1 study [4].

NEW YORK, April 03, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Neumora Therapeutics, Inc. (NASDAQ: NMRA) pursuant and/or traceable to the registration statement and related prospectus (collectively, the “Offering Documents”) issued in connection with Neumora’s September 2023 initial public offering (the “IPO”), of the important April 7, 2025 lead plaintiff deadline in the securities class action first filed by the firm. SO WHAT: If ...

Core Viewpoint - Neumora Therapeutics, Inc. is facing a class action lawsuit due to allegations of issuing misleading statements regarding its clinical trials and the efficacy of its flagship therapeutic candidate, Navacaprant [2][3]. Group 1: Allegations - The lawsuit claims that Neumora amended the original Phase Two trial inclusion criteria to include patients with moderate to severe Major Depressive Disorder (MDD) to justify its Phase Three Program [2]. - It is alleged that the company added a prespecified analysis to the Phase Two statistical analysis plan, focusing on patients suffering from moderate to severe MDD [2]. - The complaint also states that the Phase Two Trials lacked adequate data, particularly concerning the patient population size and the male-to-female ratio, which could affect the predictability of the KOASTAL-1 study results [2]. Group 2: Class Action Details - The class period for the lawsuit commenced on or about September 15, 2023, and shareholders are encouraged to register by April 7, 2025, to participate [1][3]. - Shareholders who register will be enrolled in a portfolio monitoring software to receive updates throughout the case lifecycle [3]. - There is no cost or obligation for shareholders to participate in the case [3]. Group 3: Law Firm Information - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting investors' rights against deceit and fraud [4]. - The firm aims to ensure companies adhere to responsible business practices and seeks recovery for investors who suffered losses due to misleading statements or omissions [4].

Core Viewpoint - A securities class action lawsuit has been filed against Neumora Therapeutics, Inc. in the Southern District of New York, concerning alleged misleading statements in the company's Offering Documents related to its initial public offering [1] Group 1: Allegations Against Neumora - The lawsuit claims that Neumora made materially false and/or misleading statements in its Offering Documents [2] - It is alleged that Neumora amended the Phase Two Trial inclusion criteria to include patients with moderate to severe major depressive disorder (MDD) to justify its Phase Three Program [2] - The complaint also states that the Phase Two Trials lacked adequate data regarding patient population size and gender ratio, which could affect the predictability of the KOASTAL-1 study results [2] Group 2: Lead Plaintiff Process - Investors in Neumora have until April 7, 2025, to seek appointment as a lead plaintiff representative of the class [3] - A lead plaintiff acts on behalf of all class members and typically has the largest financial interest in the case [3] - The decision to serve as a lead plaintiff does not affect an investor's ability to share in any recovery [3] Group 3: Contact Information - Kessler Topaz Meltzer & Check, LLP encourages affected Neumora investors to contact them for more information [4] - The firm has a reputation for prosecuting class actions and has recovered billions for victims of corporate misconduct [4]

Core Viewpoint - Neumora Therapeutics, Inc. is facing a class action securities lawsuit due to alleged securities fraud affecting investors who purchased its common stock since September 15, 2023 [1][2]. Class Definition - The lawsuit aims to recover losses for all individuals or entities that acquired Neumora common stock based on the Offering Documents [2]. Case Details - The complaint alleges that Neumora made false statements and concealed critical information regarding its Phase Three Program and the Phase Two trials of its flagship therapeutic candidate, Navacaprant. Specifically, it claims that: - Neumora amended the original Phase Two trial inclusion criteria to include patients with moderate to severe Major Depressive Disorder (MDD) to demonstrate statistically significant improvement [3]. - A prespecified analysis was added to the Phase Two statistical analysis plan focusing on patients with moderate to severe MDD [3]. - The Phase Two Trials lacked adequate data, particularly concerning patient population size and gender ratio, which hindered accurate predictions for the KOASTAL-1 study results [3]. Next Steps - Investors who suffered losses in Neumora Therapeutics, Inc. during the relevant timeframe have until April 7, 2025, to request appointment as lead plaintiff, although participation does not require serving in this role [4]. Why Levi & Korsinsky - Levi & Korsinsky has a strong track record in securities litigation, having secured hundreds of millions for shareholders and consistently ranking among the top securities litigation firms in the U.S. [5].

Core Viewpoint - Neumora Therapeutics, Inc. is facing a class action lawsuit due to allegations of misleading statements and failure to disclose critical information regarding its clinical trials, particularly related to its flagship therapeutic candidate, Navacaprant [3]. Group 1: Legal Action and Investor Information - The Portnoy Law Firm is representing investors who purchased Neumora common stock starting from September 15, 2023, and they have until April 7, 2025, to file a lead plaintiff motion [1]. - Investors are encouraged to contact the law firm for a complimentary case evaluation and to discuss their legal rights regarding potential claims to recover losses [2]. Group 2: Allegations Against Neumora - The complaint alleges that Neumora altered the original Phase Two trial inclusion criteria to include patients with moderate to severe Major Depressive Disorder (MDD) to justify its Phase Three Program [3]. - The company modified the Phase Two statistical analysis plan by introducing a prespecified analysis focused on patients with moderate to severe MDD, which raises concerns about the validity of the trial results [3]. - There were significant deficiencies in the Phase Two trials, particularly regarding patient population size and the male-to-female ratio, which complicates the prediction of outcomes for the KOASTAL-1 study [3].

Core Viewpoint - Neumora Therapeutics, Inc. is facing a class action lawsuit due to allegations of issuing misleading statements regarding its clinical trials and the efficacy of its flagship therapeutic candidate, Navacaprant [4]. Group 1: Lawsuit Details - The class action lawsuit is on behalf of all individuals or entities who purchased Neumora common stock during the class period starting on or about September 15, 2023 [3]. - The deadline for shareholders to register for the class action is April 7, 2025, and they are encouraged to register to monitor the case's progress [5]. Group 2: Allegations Against Neumora - The complaint alleges that Neumora amended the original Phase Two trial inclusion criteria to include patients with moderate to severe Major Depressive Disorder (MDD) to justify its Phase Three Program [4]. - It is claimed that the Phase Two Trials lacked adequate data regarding patient population size and gender ratio, which could affect the predictability of the KOASTAL-1 study results [4]. Group 3: Legal Representation - The Gross Law Firm, a nationally recognized class action law firm, is representing the shareholders and aims to protect investors' rights against deceit and fraud [6]. - The firm emphasizes its commitment to ensuring responsible business practices and seeks recovery for investors who suffered losses due to misleading statements by companies [6].